Hideyoshi Harashima
Impact in
- Biomaterials top 0.05%
- Nanoparticle-Based Drug Delivery
- Molecular Biology top 0.1%
- RNA Interference and Gene Delivery
- Advanced biosensing and bioanalysis techniques
- Lipid Membrane Structure and Behavior
- Mitochondrial Function and Pathology
Papers in
-
- RNA Interference and Gene Delivery 333
- Advanced biosensing and bioanalysis techniques 179
- Mitochondrial Function and Pathology 49
- CRISPR and Genetic Engineering 43
- Lipid Membrane Structure and Behavior 41
- Biomaterials 87
- Nanoparticle-Based Drug Delivery 84
- Co-authors
- Hidetaka AkitaKentaro KogureHiroto HatakeyamaYusuke SatoYuma YamadaIkramy A. KhalilShiroh FutakiHiroshi Kiwada
- Journals
- Journal of Controlled Release (74 papers)Biological and Pharmaceutical Bulletin (47 papers)International Journal of Pharmaceutics (43 papers)Biomaterials (20 papers)Journal of Pharmaceutical Sciences (17 papers)
- Partner nations
- JapanEgyptUnited States
In The Last Decade
Hideyoshi Harashima
558 papers receiving 25.3k citations
Hit Papers
Peers
Comparison fields: 5 of 160
- Biomaterials 5.7k
- Molecular Biology 18.6k
- Pharmaceutical Science 1.1k
- Immunology 3.4k
- Genetics 3.6k
Countries citing papers authored by Hideyoshi Harashima
This map shows the geographic impact of Hideyoshi Harashima's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hideyoshi Harashima with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hideyoshi Harashima more than expected).
Fields of papers citing papers by Hideyoshi Harashima
This network shows the impact of papers produced by Hideyoshi Harashima. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hideyoshi Harashima. The network helps show where Hideyoshi Harashima may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Hideyoshi Harashima, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 3 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 0 | |
| 4 | 2023 | 33 | |
| 5 | 2023 | 26 | |
| 6 | 2023 | 14 | |
| 7 | 2023 | 2 | |
| 8 | 2022 | 6 | |
| 9 | 2022 | 9 | |
| 10 | 2021 | 7 | |
| 11 | 2021 | 29 | |
| 12 | 2020 | 8 | |
| 13 | 2020 | 82 | |
| 14 | 2018 | 174 | |
| 15 | 2016 | 65 | |
| 16 | 細胞質及びミトコンドリア融合性エンベロープを持つ革新的ナノ担体DF-MITO-Porterを用いたミトコンドリア標的DNA供給 | 2012 | 9 |
| 17 | 2012 | 8 | |
| 18 | 2010 | 8 | |
| 19 | 2005 | 13 | |
| 20 | 2003 | 1 |
About Hideyoshi Harashima
Hideyoshi Harashima is a scholar working on Molecular Biology, Biomaterials, Immunology, Genetics and Cancer Research, having authored 568 papers that have together received 25.6k indexed citations. Recurring topics across this work include RNA Interference and Gene Delivery (333 papers), Advanced biosensing and bioanalysis techniques (179 papers), Virus-based gene therapy research (95 papers), Nanoparticle-Based Drug Delivery (84 papers), Immunotherapy and Immune Responses (57 papers), Mitochondrial Function and Pathology (49 papers), CRISPR and Genetic Engineering (43 papers) and Lipid Membrane Structure and Behavior (41 papers). The work is most often cited by research in Biomaterials (5.7k citations), Molecular Biology (18.6k citations), Pharmaceutical Science (1.1k citations), Immunology (3.4k citations) and Genetics (3.6k citations). Hideyoshi Harashima has collaborated with scholars based in Japan, Egypt and United States. Frequent co-authors include Hidetaka Akita, Kentaro Kogure, Hiroto Hatakeyama, Yusuke Sato, Yuma Yamada, Ikramy A. Khalil, Shiroh Futaki, Hiroshi Kiwada, Takashi Nakamura and Hiroyuki Kamiya. Their work appears in journals such as Journal of Controlled Release, Biological and Pharmaceutical Bulletin, International Journal of Pharmaceutics, Biomaterials and Journal of Pharmaceutical Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.